Clinical Trial Update: Vepdegestrant (ARV-471/PF-07850327) + Palbociclib vs Letrozole + Palbociclib in ER(+)/HER2(-) Advanced Breast Cancer [Phase 3]

View source ↗

Summary

Phase 3 trial comparing Vepdegestrant (ARV-471) plus palbociclib vs letrozole plus palbociclib in ER-positive/HER2-negative advanced breast cancer; the study is…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Estrogen Receptor-positive Breast Cancer

Drugs mentioned

• Letrozole (letrozole)
• Palbociclib (palbociclib)
• Vepdegestrant (ARV-471)

Snippet

Sponsor: Pfizer | Conditions: Breast Cancer | Phase 3 | Status: ACTIVE_NOT_RECRUITING